Lymphoma hub
@lymphomahub.bsky.social
13 followers 2 following 61 posts
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
Posts Media Videos Starter Packs
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Watch the full video here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd
Catch up on the latest developments in lymphoma and CLL with our coverage from #IACH 2025: https://loom.ly/VEha6BE
#lymphoma #lymsm #leusm #MedNews #MedEd
New publication 📝 Phase III results, published in Blood, show acalabrutinib + obinutuzumab significantly improved PFS and OS vs chlorambucil + obinutuzumab in treatment-naïve CLL (72-month PFS, 78.0% vs 17.2%; p < 0.0001).

Learn more: LymphomaHub.com

#CLLsm #leusm #MedNews #MedEd

🚨 NEWS 🚨
FDA grants fast track designation to EO2463, an ‘OncoMimic’ immunotherapy, for the treatment of patients with FL in the low tumor burden “watch-and-wait” setting.
Read more: https://loom.ly/jx-bpb4

#lymsm #lymphoma #MedNews #MedEd
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Listen here: https://loom.ly/1ncUMzw

#lymsm #lymphoma #MedNews #MedEd
New publication 📝 Results from the phase II COALITION, published in Journal of Clinical Oncology, show glofitamab in combination with R-CHOP or Pola-R-CHP was feasible and safe, with durable responses in patients with LBCL.

Learn more: LymphomaHub.com

#Lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
FDA grants breakthrough therapy designation to sonrotoclax, a next-generation BCL-2 inhibitor, for the treatment of R/R MCL, based on results from the BGB-11417-201 trial.
Read more: https://loom.ly/AfWxP3A
#lymsm #leusm #MedNews #MedEd
New data 📝 At #EHA2025 and #18ICML, Matthew Ku and Krish Patel, respectively, presented results from a phase Ib study investigating JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in patients with R/R LBCL.

Learn more: https://loom.ly/bobViGE

#Lymphoma #lymsm #MedNews #MedEd
New publication 📝 Phase I/II results, published in Blood Advances, show pirtobrutinib achieved 52.1% ORR in patients with R/R FL, with median DoR of 10.2 months and favorable tolerability.

Learn more: https://loom.ly/DEFIgFo

#lymsm #lymphoma #MedNews #MedEd
What are the latest updates from the phase III STARGLO trial? The Lymphoma Hub spoke to Charles Herbaux, University of Montpellier, about the 2L and 3L+ data from this trial.

Watch here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ outcomes from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.

Watch here: https://loom.ly/FdLag2Q

#lymsm #lymphoma #MedNews #MedEd
New publication 📝 Phase II PILOT study results, published in Blood Advances, show liso-cel is an effective second-line therapy for patients with LBCL, with an ORR of 80%.

Learn more: https://loom.ly/qCzLBcA

#lymphoma #MedNews #MedEd
🚨 NEWS 🚨
FDA grants fast track designation to UB-VV111, an off-the-shelf gene therapy that generates CD19-directed CAR T cells in vivo, for the treatment of R/R LBCL or CLL after ≥2 prior lines of therapy.
Read more: https://loom.ly/xeSW0c4
#lymsm #leusm #MedNews #MedEd
New publication 📝Phase III SEQUOIA Arm D cohort results, published in the Journal of Clinical Oncology, show zanubrutinib + venetoclax was effective with a favorable safety profile in patients with CLL/SLL, regardless of TP53 mutation status.

Learn more: LymphomaHub.com

#lymphoma #lymsm #MedEd
New publication 📝 A secondary analysis from the phase III HD21 trial, published in The Lancet Group, shows higher rates of gonadal function recovery in men and women with advanced cHL treated with BrECADD vs eBEACOPP.

Learn more: LymphomaHub.com

#lymphoma #lymsm #MedNews #MedEd
🚨 News 🚨
EMA CHMP has recommended the approval of a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy.
Read more: https://loom.ly/1mZhRVY
#lymphoma #lymsm #MedNews
🚨 News 🚨
EMA CHMP has recommended approval for a new subcutaneous formulation of pembrolizumab for approved indications, including classical Hodgkin lymphoma.
Read more: https://loom.ly/Pt5PnW0
#lymphoma #lymsm #MedNews #MedEd
📝 At #ICML18, the Lymphoma Hub symposium “Customizing therapy for MCL” was chaired by Gilles Salles, featuring presentations from Julie Vose, Wojciech Jurczak, and Michael Wang and concluding with an interactive Q&A session.

Learn more: https://loom.ly/5348JN4
#Lymphoma #lymsm #MedEd
📝 A new study, published in the Journal of Clinical Oncology, found that pirtobrutinib improves PFS and TTNT vs IdelaR/BR with a well-tolerated safety profile in cBTKi pretreated patients with CLL/SLL.

More news: LymphomaHub.com

#leusm #MedNews #MedEd
During the Lymphoma Hub symposium at 18ICML, the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, hosted a Q&A session with live audience participation.

Learn more: https://loom.ly/qdcrsgE
📝 During the Lymphoma Hub symposium at #18ICML, titled Customizing therapy for MCL, the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the audience.

Listen here: https://loom.ly/PRy_HK4

#Lymphoma #lymsm #MedEd
New publication 📝 Results from the phase III BRUIN CLL-321 trial published in the Journal of Clinical Oncology show that pirtobrutinib improves PFS vs IdelaR/BR in cBTKi pretreated patients with CLL/SLL.

Learn more: https://loom.ly/ngeSoHQ

#leusm #MedNews #MedEd
During the Lymphoma Hub symposium at 18ICML, Michael Wang discussed current therapies for MCL and their combinations.

Watch the full video here: https://loom.ly/hrCsHCY

📝 During the Lymphoma Hub symposium at #18ICML, Michael Wang discussed current therapies for MCL and their combinations.

Listen here: https://loom.ly/b5GWGZU

#Lymphoma #lymsm #MedEd
🚨 News 🚨

UK MHRA grants conditional market authorization to pirtobrutinib, a non-covalent BTKi, for the treatment of patients with MCL or CLL who were previously treated with a BTKi.

Read more here: https://loom.ly/E5Dt3Cc

#Lymphoma #lymsm #MedNews #MedEd